COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | |
---|---|---|---|
Apr. 30, 2017 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
Loss Contingencies [Line Items] | |||
Shares Issued | 44,696,923 | 17,392,343 | |
Research and development | $ 647,302 | $ 362,456 | |
Chairman And CEO [Member] | |||
Loss Contingencies [Line Items] | |||
Description for employee agreement rate | The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company | ||
Employment Agreements [Member] | |||
Loss Contingencies [Line Items] | |||
Accrued salary | $ 83,731 | ||
License Agreement [Member] | QSAM Therapeutics Inc [Member] | |||
Loss Contingencies [Line Items] | |||
Other Expenses | 15,101 | 97,999 | |
Royalty percentage | 4.50% | ||
Sublicense percentage | 5.00% | ||
Consulting fee | $ 8,500 | ||
Payment for license fees | $ 60,000 | ||
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member] | |||
Loss Contingencies [Line Items] | |||
Other Expenses | $ 2,000,000 | ||
Shares Issued | 500,000 | ||
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member] | |||
Loss Contingencies [Line Items] | |||
Other Expenses | $ 410,000 |
X | ||||||||||
- Definition Consulting fee. No definition available.
|
X | ||||||||||
- Definition Payment for license fees. No definition available.
|
X | ||||||||||
- Definition Royalty percentage. No definition available.
|
X | ||||||||||
- Definition Sublicense percentage. No definition available.
|
X | ||||||||||
- Definition Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Description of nature and effect of change affecting comparability of defined contribution plan. Includes, but is not limited to, change in rate of employer contributions, business combination, or divestiture. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|